版本:
中国

BRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells

May 25 Adaptimmune Therapeutics Plc

* Adaptimmune Therapeutics Plc - initiated study of NY-ESO SPEAR T-cells targeting NY-ESO in combination with keytruda in patients with multiple myeloma

* Adaptimmune Therapeutics Plc - Adaptimmune is developing NY-ESO SPEAR T-cell program under a strategic collaboration agreement with GSK Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐